SCHEMBL2099655

SCHEMBL2099655

CC(=O)c1ccc(O[Si](C(C)C)(C(C)C)C(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.55
RAB9A P51151 3/20 0.55
HPGD P15428 2/20 0.55
LMNA P02545 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
POLB P06746 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
GAA P10253 1/20 0.47
STS P08842 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
MAOB P27338 5/20 0.42
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 2/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
MAOA P21397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163425 0.85 KMT2A (0.58) HPGDSMN1; SMN2ALDH1A1KMT2A
SCHEMBL6307030 0.83 KMT2A (0.39) MAPTRAB9AHPGDLMNANPSR1
SCHEMBL18985150 0.81 CA1 (0.58) MAPTRAB9APOLBSTSSMN1; SMN2
SCHEMBL2099038 0.80 ALDH1A1 (0.42) MAPTRAB9AHPGDLMNAL3MBTL1
SCHEMBL17070018 0.80 ELANE (0.58) RAB9AHPGDNPSR1GAASTS
SCHEMBL2099154 0.80 ABCB1 (0.48) MAPTRAB9AHPGDPOLBL3MBTL1
SCHEMBL19886788 0.80 LMNA (0.55) MAPTRAB9ALMNANPSR1SMN1; SMN2
SCHEMBL2099644 0.79 GSK3B (0.59) NPC1
SCHEMBL29676430 0.79 ALDH5A1 (0.47) MAPTRAB9AHPGDLMNAPOLB
SCHEMBL4222501 0.78 PPARG (0.41) MAPTRAB9AHPGDPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138977-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-12612396-B1 Modulators of beta catenin and uses thereof DEWPOINT THERAPEUTICS, INC. (US) 2026-04-28 US disclosed
CN-114516789-B Cyclopropenones micromolecule compound and synthetic method and application thereof 暨南大学 2023-12-05 CN disclosed
US-8163770-B2 Benzoxathiin derivative MSD. K. K. (JP) 2012-04-24 US disclosed
US-20100168156-A1 Novel Benzoxathiine Derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-07-01 US disclosed
US-20090131397-A1 ESTROGEN MODULATORS PFIZER INC. 2009-05-21 US disclosed
US-20090131397-A1 ESTROGEN MODULATORS PFIZER INC. 2009-05-21 US disclosed
US-7470715-B2 Estrogen modulators PFIZER INC. (US) 2008-12-30 US disclosed
US-7470715-B2 Estrogen modulators PFIZER INC. (US) 2008-12-30 US disclosed
EP-1966170-A2 ESTROGEN MODULATORS Pfizer Products Inc. (US) 2008-09-10 EP disclosed
EP-1944301-A1 NOVEL BENZOXATHIIN DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-16 EP disclosed
WO-2007072164-A2 ESTROGEN MODULATORS PFIZER PRODUCTS INC. (US) 2007-06-28 WO disclosed
US-20070149564-A1 ESTROGEN MODULATORS PFIZER INC. (US) 2007-06-28 US disclosed
US-20070149564-A1 ESTROGEN MODULATORS PFIZER INC. (US) 2007-06-28 US disclosed
WO-1999064041-A9 MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS ADVANCED MEDICINE INC (US) 2001-05-31 WO disclosed
EP-1100519-A1 MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS Advanced Medicine, Inc. (US) 2001-05-23 EP disclosed
WO-1999064041-A1 MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS ADVANCED MEDICINE, INC. (US) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168156-A1 Novel Benzoxathiine Derivative XDH, GPR119, BRIX1 MAPT 4652/4885RAB9A 3100/4885HPGD 3172/4885
US-12612396-B1 Modulators of beta catenin and uses thereof CTNNB1, CTNND1, CTNNA1 MAPT 113/4885RAB9A 445/4885HPGD 3296/4885
US-20090131397-A1 ESTROGEN MODULATORS ESR2, GPER1, ESR1 MAPT 3878/4885RAB9A 4193/4885HPGD 327/4885
US-20260138977-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNND1, CTNNA1 MAPT 113/4885RAB9A 445/4885HPGD 3296/4885
US-20070149564-A1 ESTROGEN MODULATORS ESR2, GPER1, ESR1 MAPT 3878/4885RAB9A 4193/4885HPGD 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.